Q-omics provides the consensus-scored THAP6 profile across patient tissues and cancer cell-line models. THAP6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THAP6 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, THAP6 RNA expression shows 21,587 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where THAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THAP6 survival associations across molecular data types. THAP6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THAP6 RNA expression–survival associations across cancer types. High THAP6 expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRC, READ, ACC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THAP6 RNA expression.
This table summarizes THAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for THAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THAP6 shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, KIRP, LIHC and CHOL. The THCA box plot shows higher THAP6 RNA expression in normal versus tumor tissue (log2 FC = −0.565, t-test p < 0.001).
This table shows molecular features associated with THAP6 in patient tissues and cancer cell lines. In patient samples, THAP6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, THAP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
